{"podcast":{"title":"Hematologic Oncology Update","slug":"hematologic-oncology-update-916423","podcast_index_feed_id":916423,"rss_url":"https://feeds.captivate.fm/hematologic-oncology/","website_url":"https://www.researchtopractice.com/browse-tumor-types/hematologic-oncology","image_url":"https://artwork.captivate.fm/385e0bc2-3e77-4650-a103-033cd89470e0/VM1-kJu7V4rmiKPVI6DGtcq3.png","author":"Dr. Neil Love","episode_count":145,"summary":"Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.","last_synced_at":"2026-07-10T00:19:38.916639+00:00","page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423"},"episode":{"title":"Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting","slug":"novel-therapies-for-non-hodgkin-lymphoma-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting","published_at":"2026-07-09T13:00:00+00:00","page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423/novel-therapies-for-non-hodgkin-lymphoma-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting","show_page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423","url":"https://hematologic-oncology.captivate.fm/episode/6164-asco2026-nhl","audio_url":"https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/cfab2483-4019-4288-9fe5-bd8090f40c72.mp3","summary":"Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics: Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00) Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41) Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23) Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48) CME information and select publications","meta_description":"Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the followin…","key_points":[],"chapters":[],"topics":[],"duration_seconds":7034,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/novel-therapies-for-non-hodgkin-lymphoma-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/hematologic-oncology-update-916423/novel-therapies-for-non-hodgkin-lymphoma-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}